Zhi Feng

Dr. Zhi Feng

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Neurochemistry International
Verified
Journal Article
Closed access
URUmamaheswari Ramachandran
Umamaheswari Ramachandran
AMArulmani Manavalan
Arulmani Manavalan
HSHusvinee Sundaramurthi
Husvinee Sundaramurthi
SSSiu Kwan Sze
Siu Kwan Sze
ZFZhi Feng
Zhi Feng
Klaus HeeseKlaus Heese
Klaus Heese

20 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
ZFZhi Feng
Zhi Feng
CLchenyu lin
chenyu lin
LTLimei Tu
Limei Tu
MSMing Su
Ming Su
CSChunyu Song
Chunyu Song
LLLi Li
Li Li
Hematopoietic stem cells (HSCs) are a specialized subset of cells with self-renewal and multilineage differentiation potency, which are essential for their function in bone marrow or umbilical cord blood transplantation to treat blood disorders. Expanding the hematopoietic stem and progenitor cells (HSPCs) ex vivo is essential to understand the HSPCs-based therapies potency. Here, we established a screening system in zebrafish by adopting an FDA-approved drug library to identify candidates that could facilitate HSPC expansion. To date, we have screened 171 drugs of 7 categories, including antibacterial, antineoplastic, glucocorticoid, NSAIDS, vitamins, antidepressant, and antipsychotic drugs. We found 21 drugs that contributed to HSPCs expansion, 32 drugs’ administration caused HSPCs diminishment and 118 drugs’ treatment elicited no effect on HSPCs amplification. Among these drugs, we further investigated the vitamin drugs ergocalciferol and panthenol, taking advantage of their acceptability, limited side-effects, and easy delivery. These two drugs, in particular, efficiently expanded the HSPCs pool in a dose-dependent manner. Their application even mitigated the compromised hematopoiesis in an ikzf1−/− mutant. Taken together, our study implied that the larval zebrafish is a suitable model for drug repurposing of effective molecules (especially those already approved for clinical use) that can facilitate HSPCs expansion.